AbbVie
ABBV
2,972 hedge funds and large institutions have $164B invested in AbbVie in 2022 Q3 according to their latest regulatory filings, with 137 funds opening new positions, 1,305 increasing their positions, 1,158 reducing their positions, and 129 closing their positions.
13% more call options, than puts
Call options by funds: $2.32B | Put options by funds: $2.05B
13% more repeat investments, than reductions
Existing positions increased: 1,305 | Existing positions reduced: 1,158
6% more first-time investments, than exits
New positions opened: 137 | Existing positions closed: 129
0.02% more ownership
Funds ownership: 68.96% → 68.98% (+0.02%)
1% less funds holding
Funds holding: 3,007 → 2,972 (-35)
12% less capital invested
Capital invested by funds: $187B → $164B (-$22.9B)
16% less funds holding in top 10
Funds holding in top 10: 331 → 278 (-53)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$1.42B |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$538M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$383M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$351M |
| 5 |
JP Morgan Chase
New York
|
+$340M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$902M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$432M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$343M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$325M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$281M |
ABBV Hedge Fund Activity: Q3 2022 in Review
2,972 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2022, worth a combined $164B — down 12% from $187B a quarter earlier.
Buyers outnumbered sellers: 137 funds opened new ABBV positions and 129 closed out — a net gain of 8 holders — while 1,305 added to existing stakes and 1,158 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $1.42B. The largest seller was T. Rowe Price Associates, cutting an estimated $902M.
- 2,972 institutional investors held AbbVie (ABBV) as of Q3 2022, down from 3,007 in Q2 2022.
- Funds reported $164B of AbbVie stock for Q3 2022, down 12% quarter-over-quarter.
- 137 funds opened new AbbVie positions in Q3 2022 and 129 closed out, a net change of +8 holders.
- The largest AbbVie buyer in Q3 2022 was Capital Research Global Investors, an estimated $1.42B added.
- The largest AbbVie seller in Q3 2022 was T. Rowe Price Associates, an estimated $902M sold.
Based on aggregated 13F filings for Q3 2022.